{"id":"daily-oral-dose-of-hepcortespenlisimut-l","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Injection site or local reactions"},{"rate":null,"effect":"Mild fever or systemic symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This drug is a therapeutic vaccine candidate designed to boost T-cell and B-cell immune responses against HCV in chronically infected patients. It combines HCV-derived peptides with an immunological adjuvant to promote cell-mediated immunity, potentially allowing patients to clear persistent HCV infection or reduce viral load. The oral formulation aims to induce mucosal and systemic immune responses.","oneSentence":"Hepcortespenlisimut-L is an oral therapeutic vaccine that stimulates immune responses against hepatitis C virus (HCV) antigens to enhance viral clearance.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:31:05.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C infection (HCV)"}]},"trialDetails":[{"nctId":"NCT02256514","phase":"PHASE2","title":"Open Label Trial of Immunotherapy for Advanced Liver Cancer","status":"UNKNOWN","sponsor":"Immunitor LLC","startDate":"2014-09","conditions":"HCC, Liver Cirrhosis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["V5"],"phase":"phase_2","status":"active","brandName":"Daily oral dose of hepcortespenlisimut-L","genericName":"Daily oral dose of hepcortespenlisimut-L","companyName":"Immunitor LLC","companyId":"immunitor-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Hepcortespenlisimut-L is an oral therapeutic vaccine that stimulates immune responses against hepatitis C virus (HCV) antigens to enhance viral clearance. Used for Chronic hepatitis C infection (HCV).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}